pilocarpine

Pilocarpine Hydrochloride (NSC 5746 HCl) is an M3-type muscarinic acetylcholine receptor agonist. Pilocarpine Hydrochloride was used to make an experimental model of epilepsy.

Pilocarpine nitrate (Pilagan) is a slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.

Pilocarpine-d3 HCl is a deuterated compound of Pilocarpine HCl. Pilocarpine HCl has a CAS number of 54-71-7. Pilocarpine hydrochloride, a nonselective muscarinic acetylcholine receptor agonist, is utilized to produce an experimental model of epilepsy.

Ens-163 phosphate is a muscarinic M1 receptor agonist. It is selective.

Cinperene is an atropine-like compound that can block pilocarpine-induced salivation and lacrimation.

SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM for the D1 receptor subtype and 0.3 nM for the D5 receptor subtype). It reduces the latency of lever pressing behavior induced by cocaine in rats. Additionally, SCH-23390 can eliminate generalized seizures triggered by the chemical convulsants pilocarpine and soman, making it useful for studies on neurodegenerative diseases related to the dopamine system.

VU 0255035 is a highly selective, competitive, and brain-penetrant muscarinic M1 receptor antagonist with an IC50 of 130 nM, used to reduce pilocarpine-induced seizures in mice and to examine the role of the M1 receptor in diverse situations.

DDPM-2571 is a highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. DDPM-2571 was quickly distributed into the brain and was highly effective in the prevention of chemically-induced seizures (pentylenetetrazole and pilocarpine models) and 6-Hz convulsions. It demonstrated significant anxiolytic-like and antidepressant-like properties. DDPM-2571 had antinociceptive properties, both in the hot plate test and in the second phase of the formalin test.

TG8-260 is a second-generation EP2 antagonist developed to mitigate pathology in inflammatory-driven central and peripheral nervous system disorders. In a rat model, TG8-260 reduced neuroinflammation and gliosis in the hippocampal region following pilocarpine-induced status epilepticus. Pharmacokinetic data for TG8-260 reveal a plasma half-life of 2.14 hours and an oral bioavailability of 77.3%. Furthermore, TG8-260 acts as a potent inhibitor of CYP450 and demonstrates antagonistic activity by inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglial cells, making it suitable for research on anti-inflammatory pathways in animal models of peripheral inflammatory diseases.